Login to Your Account



Allicense 2013

Deloitte Recap Calls 2012 the 'Year of the Phase II'

By Catherine Shaffer
Staff Writer

Monday, April 29, 2013
us_resized.jpg

SAN FRANCISCO – Phase II deal values surpassed Phase III in 2012, leading a senior biopharma analyst for Deloitte Recap LLC, to say "2012 was certainly the year of the Phase II" in her talk summarizing Deloitte's analysis of 1,692 deals closed in 2012 at the firm's Allicense Conference in San Francisco on Monday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription